A Study of Chemotherapy in Patients with Immunoglobulin Light (or Heavy) Chain Amyloidosis


About this study

The aims of this prospective observational study will be to include all patients with systemic AL amyloidosis regardless of age or disease severity, in order to convey a ‘real-world’ picture of the disease, its response to myeloma-type chemotherapy regimens, associated toxicity and outcomes in terms of amyloidotic organ function, quality of life (QoL) and survival.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Group 1:
    1. Patients with high-risk cardiac amyloid as defined as:
      1. Troponin T greater than or equal to 0.035 ng/ml and NT-proBNP greater than or equal to 332 pg/ml.
  2. Group 2:
    1. Patients who have undergone high-dose chemotherapy with peripheral blood stem cell transplantation who have not achieved at least a very good partial response.
  3. Group 3:
    1. Any patient starting non-protocol therapy and willing to be followed for toxicity and QOL.

Exclusion Criteria:

  • Unwillingness to participate or inclusion on a prospective treatment trial.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Angela Dispenzieri, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer